Literature DB >> 33686103

Association between the C-reactive protein/albumin ratio and prognosis in patients with oral squamous cell carcinoma.

Kenji Yamagata1, Satoshi Fukuzawa2, Naomi Ishibashi-Kanno2, Fumihiko Uchida2, Hiroki Bukawa2.   

Abstract

The systemic inflammatory response is known to be associated with poor outcomes in patients with various types of cancer. The C-reactive protein (CRP)/albumin (Alb) ratio (CAR) has been reported as a novel inflammation-based prognostic marker. We have evaluated the prognostic value of inflammatory markers for patients with oral squamous cell carcinoma (OSCC). The study population included 205 patients treated with OSCC between 2013 and 2018. The primary predictor variable was the inflammatory markers. The primary outcome variable was overall survival (OS). Univariate and multivariate analyses were performed using a Cox proportional hazards model to identify independent prognostic factors. The CAR had the highest area under the curve (AUC) values compared with other markers in the receiver operating characteristic (ROC) curve analysis. The cutoff value for CAR was 0.032 (AUC 0.693, P < 0.001). There was a significant difference in OS when patients were stratified according to CAR, with 79.1% for CAR < 0.032 and 35% for CAR ≥ 0.032 (P < 0.001). Cox multivariate analysis identified independent predictive factors for OS: age (hazard ratio [HR] 2.155, 95% confidence interval [CI] 1.262-3.682; P = 0.005), stage (HR 3.031, 95% CI 1.576-5.827; P = 0.001), and CAR (HR 2.859, 95% CI 1.667-4.904; P < 0.001). CAR (≥ 0.032 vs. < 0.032) is a good prognostic marker in patients with OSCC in terms of age and stage.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33686103      PMCID: PMC7940640          DOI: 10.1038/s41598-021-83362-2

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  27 in total

1.  Pretreatment peripheral blood leukocytes are independent predictors of survival in oral cavity cancer.

Authors:  Cristina Valero; Daniella K Zanoni; Marlena R McGill; Ian Ganly; Luc G T Morris; Miquel Quer; Jatin P Shah; Richard J Wong; Xavier León; Snehal G Patel
Journal:  Cancer       Date:  2019-12-06       Impact factor: 6.860

2.  Pretreatment albumin level predicts survival in head and neck squamous cell carcinoma.

Authors:  Won Sub Lim; Jong-Lyel Roh; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  Laryngoscope       Date:  2017-05-31       Impact factor: 3.325

Review 3.  Cancer-related inflammation.

Authors:  Alberto Mantovani; Paola Allavena; Antonio Sica; Frances Balkwill
Journal:  Nature       Date:  2008-07-24       Impact factor: 49.962

4.  Prognostic Value of Preoperative Systemic Immunoinflammatory Measures in Patients with Esophageal Cancer.

Authors:  Yusuke Ishibashi; Hironori Tsujimoto; Shuichi Hiraki; Isao Kumano; Yoshihisa Yaguchi; Hiroyuki Horiguchi; Shinsuke Nomura; Nozomi Ito; Eiji Shinto; Suefumi Aosasa; Junji Yamamoto; Hideki Ueno
Journal:  Ann Surg Oncol       Date:  2018-07-17       Impact factor: 5.344

5.  Prognostic capacity of Systemic Inflammation Response Index (SIRI) in patients with head and neck squamous cell carcinoma.

Authors:  Cristina Valero; Laura Pardo; Aina Sansa; Jacinto Garcia Lorenzo; Montserrat López; Miquel Quer; Xavier León
Journal:  Head Neck       Date:  2019-11-21       Impact factor: 3.147

6.  Clinical Significance of the C-Reactive Protein to Albumin Ratio for Survival After Surgery for Colorectal Cancer.

Authors:  Mitsuru Ishizuka; Hitoshi Nagata; Kazutoshi Takagi; Yoshimi Iwasaki; Norisuke Shibuya; Keiichi Kubota
Journal:  Ann Surg Oncol       Date:  2015-11-03       Impact factor: 5.344

7.  The value of preoperative Glasgow Prognostic Score and the C-Reactive Protein to Albumin Ratio as prognostic factors for long-term survival in pathological T1N0 esophageal squamous cell carcinoma.

Authors:  Xiangyang Yu; Yingsheng Wen; Yongbin Lin; Xuewen Zhang; Yongqiang Chen; Weidong Wang; Gongming Wang; Lanjun Zhang
Journal:  J Cancer       Date:  2018-02-12       Impact factor: 4.207

8.  The prognostic value of C-reactive protein/albumin ratio in nasopharyngeal carcinoma: a meta-analysis.

Authors:  Nan Gao; Ruo-Nan Yang; Zhen Meng; Wan-Hai Wang
Journal:  Biosci Rep       Date:  2018-11-13       Impact factor: 3.840

9.  Prognostic value of pretreatment C-reactive protein/albumin ratio in nasopharyngeal carcinoma: A meta-analysis of published literature.

Authors:  Xiaodi Yang; Hongjian Liu; Minfu He; Meitian Liu; Ge Zhou; Ping Gong; Juan Ma; Qi Wang; Wenjing Xiong; Zheng Ren; Xuanxuan Li; Xiumin Zhang
Journal:  Medicine (Baltimore)       Date:  2018-07       Impact factor: 1.889

10.  Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis.

Authors:  Zhenhua Liu; Hongtai Shi; Longyun Chen
Journal:  BMC Cancer       Date:  2019-11-29       Impact factor: 4.430

View more
  4 in total

1.  Clinical risk factors for severity and prognosis of antiresorptive agent-related osteonecrosis of the jaw: a retrospective observational study.

Authors:  Masanori Nashi; Toshinori Hirai; Takuya Iwamoto; Toshihiko Takenobu
Journal:  J Bone Miner Metab       Date:  2022-09-27       Impact factor: 2.976

2.  The Systemic Inflammation Response Index as an Independent Predictor of Survival in Breast Cancer Patients: A Retrospective Study.

Authors:  Mengliu Zhu; Li Chen; Xiangyi Kong; Xiangyu Wang; Yi Fang; Xingrui Li; Jing Wang
Journal:  Front Mol Biosci       Date:  2022-02-28

3.  Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.

Authors:  Kosei Kubota; Ryohei Ito; Norihiko Narita; Yusuke Tanaka; Ken Furudate; Natsumi Akiyama; Chuang Hao Chih; Shotaro Komatsu; Wataru Kobayashi
Journal:  BMC Cancer       Date:  2022-04-07       Impact factor: 4.430

4.  RuleFit-Based Nomogram Using Inflammatory Indicators for Predicting Survival in Nasopharyngeal Carcinoma, a Bi-Center Study.

Authors:  Chao Luo; Shuqi Li; Qin Zhao; Qiaowen Ou; Wenjie Huang; Guangying Ruan; Shaobo Liang; Lizhi Liu; Yu Zhang; Haojiang Li
Journal:  J Inflamm Res       Date:  2022-08-24
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.